At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
pazopanib hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma
In Brief
A Phase 2 clinical trial evaluating laboratory biomarker analysis and pazopanib hydrochloride for Advanced Malignant Mesothelioma and 2 related conditions. Completed, enrolled 34 participants across 1 site.
Detailed Summary
This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2007
Primary CompletionApr 2009
Study CompletionMay 2013
TodayJul 2026
First PostedApr 13, 2007
Enrollment StartMar 1, 2007
Primary CompletionApr 1, 2009
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.2 years ago
Interventions
laboratory biomarker analysisother
Correlative study
pazopanib hydrochloridedrug
Given orally